Your trusted source for investing success

Tag: Europe

GéoMégA subsidiary Innord Separates Nd and Dy with 95% Purity in addition to 99.8% Purity Cobalt from Industrial Residue

Geomega Resources (“GéoMégA” or the “Corporation”) (TSX.V: GMA) is pleased to announce that Innord (“Innord”), a private subsidiary controlled by GéoMégA, successfully processed an industrial residue and produced a high purity rare earth elements concentrate (“REE”), a high purity cobalt product and is advancing separation of Neodymium and Dysprosium using

Q BioMed Announces Development Partnership With Sphaera Pharma

Q BioMed Announces Development Partnership With Sphaera Pharma

Q BioMed Inc. (OTCQB:QBIO), a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for pediatric developmental nonverbal disorder.

 “The goal of our collaboration with Sphaera Pharma is to put the patient first, especially since QBM-001 targets a rare subset of toddlers

Hannan Drills 4.0 Metres @ 0.7% Zinc, 8.9% Lead and 31 G/t Silver (8.6% ZnEq) in First Step-out Hole at Kilbricken, Ireland

Hannan Drills 4.0 Metres @ 0.7% Zinc, 8.9% Lead and 31 G/t Silver (8.6% ZnEq) in First Step-out Hole at Kilbricken, Ireland

Hannan Metals (TSXV:HAN) is pleased to announce drill results from the second hole completed in its resource expansion program at the 100%-owned Kilbricken zinc-lead-silver-copper deposit in County Clare, Ireland.  Thirteen holes are planned in this 8,500 metre drill program, scheduled to be completed during the first quarter of 2018.

Key Points:

Significant mineralization was

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.

 “The opening of this

Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Western Copper and Gold CEO Paul West-Sells

URL: https://investingnews.com/daily/resource-investing/precious-metals-investing/gold-investing/western-copper-gold-ceo-paul-west-sells/